ENTX — Entera Bio Ltd.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1638097 ·
Israel
Last close
$1.20
Market Cap
$59.15M
52W High
$1.43
52W Low
$0.91
ADV30
78,818
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -3,539,000 | -3,505,000 | 13,129,000 | 4,137,000 | 2,442,000 |
| Dec 2025 | 0 | 0 | -3,042,000 | -3,016,000 | 15,993,000 | 7,108,000 | 2,892,000 |
| Sep 2025 | 0 | 0 | -3,256,000 | -3,200,000 | 17,407,000 | 8,574,000 | 2,173,000 |
| Jun 2025 | 0 | 0 | -2,668,000 | -2,656,000 | 19,667,000 | 10,858,000 | 2,411,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,370,000
Investing CF
$-107,000
Financing CF
$13,710,000
CapEx
$-107,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.27
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-125,366,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-11,529,000
Pretax Income TTM
$-11,439,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-12,476,000
Free Cash Flow
$-4,841,625
Enterprise Value
$54,396,880
Total Cash
$4,137,000
Total Debt
$448,000
Shares Out
49,290,234
Trailing EPS
$-0.26
Book Value
$0.23
ROE
-82.3%
ROA
-45.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,000 | -11,529,000 | -11,439,000 | 15,993,000 | 2,892,000 | — | -7,370,000 |
| Dec 2024 | 181,000 | -9,585,000 | -9,541,000 | 9,390,000 | 1,310,000 | — | -6,818,000 |
| Dec 2023 | 0 | -8,891,000 | -8,889,000 | 11,765,000 | 1,379,000 | — | -7,310,000 |
| Dec 2022 | 134,000 | -13,017,000 | -13,071,000 | 13,127,000 | 1,373,000 | — | -12,499,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INKT | MiNK Therapeutics, Inc. | $60.83M | $12.21 | — |
| TCRX | TScan Therapeutics, Inc. | $54.96M | $0.90 | — |
| IMA | ImageneBio, Inc. | $64.18M | $5.69 | — |
| EXOZ | EXOZYMES INC. | $53.67M | $6.33 | — |
| BSEM | BioStem Technologies, Inc. | $66.24M | $3.90 | — |
News headlines (Yahoo Finance, 1h cache)
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
2026-06-16 12:33 · Yahoo
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
2026-06-15 12:45 · Yahoo
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline
2026-05-28 12:50 · Yahoo
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
2026-05-08 20:05 · Yahoo
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
2026-04-29 16:00 · Yahoo
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near
2026-04-24 23:33 · Yahoo
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
2026-04-20 15:59 · Yahoo
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
2026-04-14 12:45 · Yahoo
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
2026-04-02 12:45 · Yahoo
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
2026-03-27 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.